Immunitor Presents Positive TB Treatment Data at African Conference
28 Febrero 2011 - 5:22AM
Immune Network Ltd. (Pink Sheets:IMMFF) advises that Immunitor will
present latest results from its imm01 clinical trial in
tuberculosis patients in Abuja, Nigeria at the 18th Union TB and
Lung Diseases Conference of the African Region, 2nd to 5th March,
2011.
Clinical evidence indicates that Immunitor's V5:
- Clears TB bacteria from patient sputum in one month
- Clears symptoms of TB such as fever and inflammation
- Helps underweight patients re-gain lost weight
- Is effective for drug resistant TB, as well as TB with HIV
co-infection
- Reduces adverse side effects of conventional drugs
- Is safe and free of adverse effects even in severely ill
patients
About 2,000 participants are expected at the African conference,
which will deliberate on problems and solutions for tuberculosis,
asthma, pneumonia, lung cancer, TB and HIV, funding for TB
research, and new preventive, diagnostic and curative methods to
fight TB. In addition, the conference will raise awareness of new
developments in the area of equipment and treatment (for further
information see:
http://afrouniontbconf2011.org/en/welcome.html).
The Immunitor presentation will summarize data from the
120-patient imm01 phase II trial in Ukraine. Preliminary interim
results were published in two peer reviewed journals earlier this
year (see http://www.ncbi.nlm.nih.gov/pubmed/21182457 and
http://www.ncbi.nlm.nih.gov/pubmed/21244690 ). The study, conducted
by internationally recognized experts in TB immunotherapy, compared
V5 immunotherapy to placebo among treatment refractory tuberculosis
cases including re-treated TB, multi-drug resistant (MDR-TB) and TB
with HIV co-infection. After one month, 44/50 patients (88%) became
sputum smear negative in the V5 group, whereas only 7/38 (18.4%) in
placebo group had converted. The high conversion rate in
V5-receiving subjects was similar regardless whether TB was
drug-sensitive or drug-resistant or with HIV co-infection. V5 also
down-regulated TB-associated inflammation as shown by normalization
of mean elevated leukocyte counts and decreased erythrocyte
sedimentation rate. V5 was also associated with improvement in
weight gain, another important endpoint in TB treatment. No adverse
side effects or reactivation of TB attributable to V5 were seen at
any time. The investigators concluded that V5 was safe and
effective as an immune adjunct to chemotherapeutic management of TB
and can shorten substantially the duration of treatment.
After AIDS, tuberculosis is the second most common cause of
death from an infectious disease, with approximately 2 million
people dying each year. Current treatments are not fully effective,
particularly against multi-drug resistant TB (MDR-TB) and HIV-TB,
and strenuous treatment regimens lasting for up to 2 years are
required.
"Immunitor's products, some of which are approved for sale in
African countries, including Nigeria, offer effective and safe
treatment solutions. Nigeria ranks 4th among high burden countries
where TB is rampant. V5 is inexpensive, easy to administer, stable
at tropical temperature, and is made from readily available
sources, which suits ideally developing countries," said Vichai
Jirathitikal, co-founder and co-inventor of the Immunitor oral
vaccine platform. For additional information about Immunitor
company, please visit http://www.immunitor.com.
The website for Immune Network is at
http://www.immune-network.com. The Immune Network Ltd. logo is
available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8008.
Safe Harbor Statement
The information in this release, other than historical
information, may be considered forward-looking statements within
the provisions of the Private Securities Litigation Reform Act of
1995. Projection and other forward-looking statements and
management expectations regarding future events and/or financial
performance of the Company -- although given in good faith -- are
inherently uncertain and actual events and/or results may differ
materially.
CONTACT: Immune Network Ltd
IMMFF@yahoo.com
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024